Drugs / SOM230C
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01434069 | Sep 2011 → Dec 2015 | digestive system neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00859040 | Mar 2009 → Dec 2011 | meningioma | Patrick Y. Wen, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOM230C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00859040 ↗ |
| Route | Intramuscular | “60 mg intramuscularly” NCT00859040 ↗ |